Zenas BioPharma (ZBIO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.75
- Surprise
- —
- Revenue (period 2026-06-30)
- $1.0M
- Score today
- 4.9/10
Revenue source: xbrl.
Coverage in the report window
- Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32 — benzinga, 2026-08-14
- Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target — benzinga, 2026-08-14
- Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target — benzinga, 2026-08-14
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZBIO Sell at 4.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: obexelimab
- Quality below floor (1.5 < 4.0)
- Momentum score 3.7/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.50
- Price target
- $40.89
- Stop
- $25.58
- Upside to target
- +48.7%
- Reward-to-risk
- 3.6:1
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
ZBIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.93B
- P/E (fwd)
- -6.4
- 52-week range
- $13.50–$44.60
- Off 52-week high
- 38.3%
- RSI (14)
- 26
- Volume vs avg
- 1.46×
- Score today
- 4.9/10